Dual Chamber Syringes & Injectors to 2022
|発行||Greystone Research Associates||商品コード||281703|
In terms of formulation market share gains, lyophilized injectable drugs are the fastest growing drug formulation segment. From 1990 to 1998 the share of newly approved lyophilized drugs as a share of all injectable/infusible drugs was 11.9%. In 2011, it was 41% and in 2013, injectable/infusible drugs requiring reconstitution made up half of all new approvals. Because a significant number of these drugs are developed for self-administration, they present special challenges for developers. Dual chamber injection devices - designed to simplify reconstitution without patient handling of drug or diluent - have become the mainstay delivery option for this class of drugs. As lyophilized injectables continue to increase in number and market share, dual chamber syringes and injectors will experience double-digit annual unit growth.
The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.
As technology and products evolve, the level of precision in management decisions required to enable effective company performance is increasing. Such precision cannot be achieved without timely and accurate data about the company's macroscopic operating environment. The information that you and your management team require to execute your business and market strategies is unique to your organization and business model. This is why - in addition to the multi-client reports you will find on our site - we offer client-specific research services that start with customer-defined needs and culminate in assessments and analysis that answer the questions that represent risk to your business strategy. To discuss Greystone's Customer Defined Research services, we invite you to contact us.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
In the past two decades, drug delivery has become a major factor in the advancement of the quality of life and a key factor in the business success of pharmaceutical companies. During this time, syringes and injectors have evolved considerably to address the changing demands of clinicians and their patients. In particular, the appearance and refinement of disposable drug cartridges has created unique opportunities for developers of injectable drugs. For single dose devices, prefilled cartridges contain the exact deliverable dose desired. The custom of overfilling vials to insure availability of the desired dose allows for the possibility of dosing errors that are eliminated with cartridge systems. For recombinant drugs that have an extremely high cost per dose, the economics associated with exact filling are compelling.
Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.